Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)

NCT04989218 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Slow accrual and study sponsor decision.

Conditions

Cholangiocarcinoma

Interventions

DRUG: Novel combination of chemotherapy and immunotherapy

Sponsor

University of Alabama at Birmingham